Genomics of Immune Diseases and New Therapies∗

Michael Lenardo, Bernice Lo, Carrie L. Lucas

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

Genomic DNA sequencing technologies have been one of the great advances of the 21st century, having decreased in cost by seven orders of magnitude and opening up new fields of investigation throughout research and clinical medicine. Genomics coupled with biochemical investigation has allowed the molecular definition of a growing number of new genetic diseases that reveal new concepts of immune regulation. Also, defining the genetic pathogenesis of these diseases has led to improved diagnosis, prognosis, genetic counseling, and, most importantly, new therapies. We highlight the investigational journey from patient phenotype to treatment using the newly defined XMEN disease, caused by the genetic loss of the MAGT1 magnesium transporter, as an example. This disease illustrates how genomics yields new fundamental immunoregulatory insights as well as how research genomics is integrated into clinical immunology. At the end, we discuss two other recently described diseases, CHAI/LATAIE (CTLA-4 deficiency) and PASLI (PI3K dysregulation), as additional examples of the journey from unknown immunological diseases to new precision medicine treatments using genomics.

Original languageEnglish
Pages (from-to)121-149
Number of pages29
JournalAnnual Review of Immunology
Volume34
DOIs
Publication statusPublished - 20 May 2016
Externally publishedYes

Fingerprint

Immune System Diseases
Genomics
Inborn Genetic Diseases
Precision Medicine
Clinical Medicine
Genetic Counseling
Therapeutics
Allergy and Immunology
Phosphatidylinositol 3-Kinases
DNA Sequence Analysis
Research
Magnesium
Technology
Phenotype
Costs and Cost Analysis

Keywords

  • Biochemical
  • Genomics
  • Immune disorder
  • Mechanism
  • Targeted therapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Medicine(all)

Cite this

Genomics of Immune Diseases and New Therapies∗. / Lenardo, Michael; Lo, Bernice; Lucas, Carrie L.

In: Annual Review of Immunology, Vol. 34, 20.05.2016, p. 121-149.

Research output: Contribution to journalReview article

Lenardo, Michael ; Lo, Bernice ; Lucas, Carrie L. / Genomics of Immune Diseases and New Therapies∗. In: Annual Review of Immunology. 2016 ; Vol. 34. pp. 121-149.
@article{15a029a5ccb14ebc9153310becea00cf,
title = "Genomics of Immune Diseases and New Therapies∗",
abstract = "Genomic DNA sequencing technologies have been one of the great advances of the 21st century, having decreased in cost by seven orders of magnitude and opening up new fields of investigation throughout research and clinical medicine. Genomics coupled with biochemical investigation has allowed the molecular definition of a growing number of new genetic diseases that reveal new concepts of immune regulation. Also, defining the genetic pathogenesis of these diseases has led to improved diagnosis, prognosis, genetic counseling, and, most importantly, new therapies. We highlight the investigational journey from patient phenotype to treatment using the newly defined XMEN disease, caused by the genetic loss of the MAGT1 magnesium transporter, as an example. This disease illustrates how genomics yields new fundamental immunoregulatory insights as well as how research genomics is integrated into clinical immunology. At the end, we discuss two other recently described diseases, CHAI/LATAIE (CTLA-4 deficiency) and PASLI (PI3K dysregulation), as additional examples of the journey from unknown immunological diseases to new precision medicine treatments using genomics.",
keywords = "Biochemical, Genomics, Immune disorder, Mechanism, Targeted therapy",
author = "Michael Lenardo and Bernice Lo and Lucas, {Carrie L.}",
year = "2016",
month = "5",
day = "20",
doi = "10.1146/annurev-immunol-041015-055620",
language = "English",
volume = "34",
pages = "121--149",
journal = "Annual Review of Immunology",
issn = "0732-0582",
publisher = "Annual Reviews Inc.",

}

TY - JOUR

T1 - Genomics of Immune Diseases and New Therapies∗

AU - Lenardo, Michael

AU - Lo, Bernice

AU - Lucas, Carrie L.

PY - 2016/5/20

Y1 - 2016/5/20

N2 - Genomic DNA sequencing technologies have been one of the great advances of the 21st century, having decreased in cost by seven orders of magnitude and opening up new fields of investigation throughout research and clinical medicine. Genomics coupled with biochemical investigation has allowed the molecular definition of a growing number of new genetic diseases that reveal new concepts of immune regulation. Also, defining the genetic pathogenesis of these diseases has led to improved diagnosis, prognosis, genetic counseling, and, most importantly, new therapies. We highlight the investigational journey from patient phenotype to treatment using the newly defined XMEN disease, caused by the genetic loss of the MAGT1 magnesium transporter, as an example. This disease illustrates how genomics yields new fundamental immunoregulatory insights as well as how research genomics is integrated into clinical immunology. At the end, we discuss two other recently described diseases, CHAI/LATAIE (CTLA-4 deficiency) and PASLI (PI3K dysregulation), as additional examples of the journey from unknown immunological diseases to new precision medicine treatments using genomics.

AB - Genomic DNA sequencing technologies have been one of the great advances of the 21st century, having decreased in cost by seven orders of magnitude and opening up new fields of investigation throughout research and clinical medicine. Genomics coupled with biochemical investigation has allowed the molecular definition of a growing number of new genetic diseases that reveal new concepts of immune regulation. Also, defining the genetic pathogenesis of these diseases has led to improved diagnosis, prognosis, genetic counseling, and, most importantly, new therapies. We highlight the investigational journey from patient phenotype to treatment using the newly defined XMEN disease, caused by the genetic loss of the MAGT1 magnesium transporter, as an example. This disease illustrates how genomics yields new fundamental immunoregulatory insights as well as how research genomics is integrated into clinical immunology. At the end, we discuss two other recently described diseases, CHAI/LATAIE (CTLA-4 deficiency) and PASLI (PI3K dysregulation), as additional examples of the journey from unknown immunological diseases to new precision medicine treatments using genomics.

KW - Biochemical

KW - Genomics

KW - Immune disorder

KW - Mechanism

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84969791252&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969791252&partnerID=8YFLogxK

U2 - 10.1146/annurev-immunol-041015-055620

DO - 10.1146/annurev-immunol-041015-055620

M3 - Review article

C2 - 26735698

AN - SCOPUS:84969791252

VL - 34

SP - 121

EP - 149

JO - Annual Review of Immunology

JF - Annual Review of Immunology

SN - 0732-0582

ER -